RETRACTED ARTICLE: Prophylactic antiemetic efficacy of granisetron in patients with and without previous postoperative emesis

  • Yoshitaka Fujii
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Reports of Investigation



To evaluate the efficacy of granisetron, a selective antagonist of 5-hydroxytryptamine type 3 receptors. in the prevention of PONV in patients with and without previous postoperative emesis undergoing general anaesthesia for major gynaecological surgery.


In a randomized, double-blind, placebo-controlled trial of 90 women with (n=40) and without (n = 50) a history of PONV the patients received either granisetron (40 μg·kg−1) or placebo (saline)iv immediately before induction of anaesthesia. The same standard general anaesthetic technique, which consisted of isoflurane in nitrous oxide and oxygen and avoided opioids, was used. Nausea, vomiting and safety assessments were performed during the first 24 hr after anaesthesia.


The incidence of PONV was 70% and 25% after administration of placebo and granisetron in patients with previous PONV (P < 0.05), and was 40% and 8% in patients without it, respectively (P < 0.05). The incidence of adverse events postoperatively were not different among the treatment groups.


Granisetron 40 μg·kg given prior to anaesthesia reduces the incidence of PONV in patients with a history of PONV as well as in patients without it.



Évaluer l’efficacité du granisetron, un antagoniste sélectif des récepteurs de type 3 de la 5-hydroxytryptamine. administré pour prévenir les nausées et les vomissements postopératoires (NVPO) à des patientes auparavant exemptes ou ayant souffert de cette complication et soumises à un anesthésie générale pour une intervention gynécologique majeure.


Étude aléatoire, à double insu, contrôlée avec placebo. Quatre-vingt-dix femmes sans (n = 40) ou avec une histoire antérieure (n = 40) de NVPO recevaient du granisetron (40 μg·kg−1) ou un placeboiv immédiatement avant l’induction de l’anesthésie. La même technique standard d’anesthésie comprenant de l’isoflurane, du protoxyde d’azote en oxygène sans morphmique. Les évaluations des nausées, des vomissements et des conditions de sécurité étaient réalisées pendant les 24 h suivant l’anesthésie.


L’incidence des NVPO était respectivement de 70% et de 25% après l’administration du placebo et du granisetron chez les patientes ayant souffert de NVPO et de 40% et de 8% chez les patientes exemptes (P < 0,05). L’incidence de complications était la même pour les deux groupes.


Le gramsetron 40 μg·kg−1 administré avant une anesthésie à des patientes auparavant exemptes et ayant souffert de NVPO réduit l’incidence de cette complication.


  1. 1.
    Mckenzie R, Wadhwa RK, Uy NTL, et al. Antiemtic effectiveness of intramuscular hydroxyzine compared with intramuscular droperidol. Anesth Analg 1981; 60: 783–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Lerman J. Surgical and patient factors involved in postoperative nausea and vomiting. Br J Anaesth 1992; 69: 24S-32.PubMedCrossRefGoogle Scholar
  4. 4.
    Purkis IE. Factors that influence postoperative vomiting. Can Anaesth Soc J 1964; 11: 335–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Leeser J, Lip H. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. Anesth Analg 1991; 72: 751–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Bodner M, White PF. Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg 1991; 73: 250–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Kenny GNC, Oates JDL, Leeser J, et al. Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. Br J Anaesth 1992; 68: 466–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Dupeyron JP, Conseiller C, Levarlet M, et al. The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. Anaesthesia 1993; 48: 214–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Andrews PLR, Bhandari P, Davey PT, Bingbam S, Marr HE, Blower PR. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992; 28A: S2–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Fujii Y, Toyooka H, Tanaka H. Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness. Can J Anaesth 1996; 43: 110–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Bermudez J, Boyle EA, Miner WD, Sanger GJ. The antiemetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989: 24: 45–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs (I). Optimal dose-finding study. (Japanese) J Clin Ther Med 1990; 6: 49–61.Google Scholar

Copyright information

© Canadian Anesthesiologists 1997

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hiroyoshi Tanaka
    • 1
  • Hidenori Toyooka
    • 2
    • 1
  1. 1.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan
  2. 2.Department of AnaesthesiologyUniversity of Tsukuba Institute of Clinical MedicineIbarakiJapan

Personalised recommendations